Compare Quest Diagnostics Inc (DGX) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Five9 Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Five9 Inc trades at $36.4 (market cap $2.63B). The key difference: Quest Diagnostics Inc is far larger — about 9.7× Five9 Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Five9 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Five9 Inc for 72 Days on average.
| DGX | FIVN | |
|---|---|---|
Market Cap | $25.48B | $2.63B |
Volume | 941,866 | 1,864,393 |
Sector | Health | Technology |
52-Week High | $247.45 | $38.65 |
52-Week Low | $173.49 | $13.61 |
Typical Hold Time | 56 Days | 72 Days |
Enterprise Value | $31.23B | $2.78B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Five9 (FIVN) is trading at $35.15, up 4.06% with strong technical momentum and bullish moving average signals. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability as net income turned positive at $39.42M. Recent quarterly earnings consistently beat expectations, while AI revenue surged 78% YoY to $39M in Q2 2026. The stock trades near resistance at $35 with solid institutional support despite recent insider selling activity.
FIVN presents growth potential driven by AI contact center adoption and subscription revenue expansion, but faces valuation concerns with a 51.69 P/E ratio. Key risks include competitive pressure in CCaaS markets and execution challenges in maintaining current growth trajectory. Analyst consensus remains bullish with 61% buy ratings and $34 price target, though current price exceeds consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
